Methods: A double-blind crossover trial was performed to compare the treatment of COPD patients with an SABA (20 mu g of inhaled procaterol) versus a placebo. The percentage of regional lung sound energy [quantitative lung data (QLD)] was evaluated with VRI. VRI, spirometry, and impulse oscillometry (IOS) were performed immediately before and 30 min after SABA administration. Results: Ten male patients (69.6 +/- 14.2 years of age, percentage predicted forced expiratory volume in 1 s:43.8 +/- 16.9%) were

evaluated. The use of an SABA produced significant functional SHP099 price improvements in the spirometric and IOS measurements. Among the homogeneous emphysema patients (n = 7), the upper-lung QLD decreased (from 24.2 +/- 5.8 to 18.8 +/- 6.1%, p < 0.05) and the lower-lung QLD increased (from 37.9 +/- 12.7 to 46.1 +/- 14.3%, p < 0.05) following SABA

inhalation. However, the significant redistribution of the regional lung QLD to the lower-lung field was not observed in 2 of the GS-9973 3 inhomogeneous emphysema patients. Conclusion: The additional use of an SABA by COPD patients improved their pulmonary function, which was accompanied by changes in regional lung air flow. The distribution of emphysematous lesions and the bronchial reactivity to SABA appeared to affect the redistribution of the lung sounds following bronchodilator administration. Copyright (C) 2013 S. Karger AG, Basel”
“It is interesting to assess the hitherto knowledge, on breast cancer in reproductive and young females, aged <35. Even if breast cancer is rare in this group, it is, also physically and emotionally devastating. It is characterized by worse prognosis and outcome, in a stage of life, which is delicate for the female patients. This rare subgroup of breast cancer patients is ought to be the center of investigation in future studies. This paper’s mail goal is to elucidate this entity, by presenting several aspects of the disease including risk factors, therapy, natural history and major differences between the groups of breast cancer patients and last but not least, the psychosocial features of this clinical entity, by reviewing the

current and past medical literature till April 2011. (C) 2011 Elsevier Ltd. All rights reserved.”
“Single-crystalline ZnO nanorods were implanted with 30 keV Ga(+) ions and fluences between 5×10(12) and 1.5×10(16) cm(-2). Annealing PF-03084014 concentration treatments at temperatures up to 700 degrees C for 1 h were carried out to reduce implantation-induced structural defects. The structural and optical properties of the nanorods were studied by transmission electron microscopy (TEM) and cathodoluminescence (CL) spectroscopy. TEM shows that extended implantation defects vanish completely in nanorods implanted with doses up to 5×10(13) cm(-2) after annealing at 700 degrees C. Dislocation loops remain after implantation with higher fluences. The CL intensity of as-grown nanorods and implanted ZnO nanorods is low.